Becton, Dickinson and Co. (BDX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention produc...
Becton, Dickinson and Co.'s revenue increased 8.2% year over year, from $20.18B to $21.84B.
Net income decreased 1.6% over the same period, from $1.71B to $1.68B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 75% in total.
Total debt remained relatively stable at $19.18B.
The debt-to-equity ratio stands at 0.76, indicating a moderate leverage profile.
Operating cash flow declined 10.8% to $3.43B.
Becton, Dickinson and Co. maintains a moderate net profit margin of 7.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2024 | $4.71B-67.1% | $281.0M | $2.03B | $439.0M | $855.0M | $52.27B | $16.11B | $25.33B |
| Q2 FY2024 | $9.75B+107.2% | $818.0M | $4.33B | $1.17B | $1.37B | $54.16B | $18.01B | $25.65B |
| Q3 FY2024 | $14.74B+51.2% | $1.30B | $6.64B | $1.77B | $2.67B | $55.58B | $19.32B | $25.87B |
| Q1 FY2025 | $5.17B-64.9% | $303.0M | $2.23B | $453.0M | $693.0M | $54.66B | $18.76B | $25.20B |
| Q2 FY2025 | $10.44B+102.0% | $611.0M | $4.49B | $1.00B | $857.0M | $54.47B | $19.27B | $25.24B |
| Q3 FY2025 | $15.95B+52.8% | $1.19B | $7.13B | $1.88B | $2.08B | $54.90B | $19.34B | $25.47B |
| Q1 FY2026 | $5.25B-67.1% | $382.0M | $2.41B | $552.0M | $657.0M | $54.84B | $19.54B | $25.28B |
| Q2 FY2026 | $9.20B+75.2% | $72.0M | $4.21B | $562.0M | $1.33B | $50.83B | $17.28B | $24.13B |
Balance Sheet Summary (Latest Period)
Total Assets
$55.33B
Total Liabilities
$29.93B
Total Equity
$25.39B
Cash & Equivalents
$649.0M
Total Debt
$19.18B
Current Assets
$9.26B
Current Liabilities
$8.31B
Retained Earnings
$16.62B